APA (7th ed.) Citation

A, T., G, M., F, S., D, N., F, G., G, D. A., . . . A, P. (2026). Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study. American journal of therapeutics. https://doi.org/10.1097/MJT.0000000000002171

Chicago Style (17th ed.) Citation

A, Tursi, et al. "Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study." American Journal of Therapeutics 2026. https://doi.org/10.1097/MJT.0000000000002171.

MLA (9th ed.) Citation

A, Tursi, et al. "Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study." American Journal of Therapeutics, 2026, https://doi.org/10.1097/MJT.0000000000002171.